Yunnan Baiyao Group
Pharmaceutical | |
Headquarters | , China |
---|---|
Revenue | RMB 22.6 billion (2016)[1] |
Website | Website |
Yunnan Baiyao Group Co., Ltd is a Chinese
The Government Pension Fund of Norway has excluded the company from investments since 21 December 2021, since the company "uses and sells body parts from pangolins which is a globally endangered species".[3]
As of 2024 state, individual investors hold 29% of the shares and private companies hold 35%. The three largest shareholders hold 58 per cent of the company's shares.[4]
Corporate affairs
As of December 31, 2007, the company had 12 subsidiaries, engaged in the
Products
Its core product range includes the
Collaboration with Huawei
On 25 July 2022, Yunnan Baiyao Group signed a cooperation agreement with Huawei for research and development of artificial intelligence drugs.[5]
Violations of fundamental norms
On 21 December 2021, the Government Pension Fund of Norway, the world's largest sovereign wealth fund, divested from the company. The reason for the divestment and exclusion of the company is "due to unacceptable risk that the company contributes to serious environmental damage".[6] More specifically, the company "uses and sells body parts from pangolins which is a globally endangered species".[3]
See also
References
- ^ "Yunnan Baiyao Group Co. Ltd. A". Wall Street Journal.
- ^ Schuman, Michael (23 August 2017). "How One Company Brought Traditional Chinese Medicine To The Modern World And Made Billions". Forbes. Retrieved 13 September 2017.
- ^ a b "Yunnan Baiyao Group Co Ltd". 21 December 2021.
- ^ "While individual investors own 29% of Yunnan Baiyao Group Co". SimplyWall. Archived from the original on 2024-03-29. Retrieved 2024-03-29.
- ^ "Yunnan Baiyao Group Cooperates With Huawei for AI Drug Development". Pandaily. Archived from the original on 2023-11-17. Retrieved 2024-03-28.
- ^ "Decisions on observation and exclusion". 21 December 2021.